Literature DB >> 11592063

LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathway.

N Iouzalen1, S Andreae, S Hannier, F Triebel.   

Abstract

The threshold, extent and termination of TCR activation is controlled in part by inhibitory co-receptors expressed on activated T cells. The lymphocyte activation gene product (LAG-3), a ligand for MHC class II molecules co-caps with the CD3/TCR complex and inhibits cell proliferation and cytokine secretion in response to CD3 signaling. We first investigated whether LAG-3 is localized in activated T cells in detergent-resistant membrane rafts enriched in glycosphingolipids and cholesterol. We showed that both LAG-3 and MHC class II are present in the cell fraction of glycosphingolipid-rich complexes (GSL complexes) before the assembly of the immunological synapse by CD3/TCR complex cross-linking. Using the LAG-3 intracytoplasmic region as bait in the yeast two-hybrid cloning system, we next identified a novel protein termed LAP for LAG-3-associated protein. LAP is encoded by a 1.8-kb RNA message in lymphocytes and encodes a 45-kDa protein that is expressed in most tissues. We showed that LAP binds specifically in vitro and in vivo to the Glu-Pro (EP) repeated motif present in the LAG-3 intracytoplasmic region. LAP also binds to the EP motif of another functionally important receptor, the PDGFR. Thus, LAP is a candidate molecule for a new type of signal transduction and/or coupling of clustered rafts to the microtubule networks that could explain how negative signaling of co-receptors may occur through molecules devoid of any immunoreceptor tyrosine-based inhibitory motif consensus sequence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592063     DOI: 10.1002/1521-4141(2001010)31:10<2885::aid-immu2885>3.0.co;2-2

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  22 in total

1.  Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation.

Authors:  Takeo K Maeda; Daisuke Sugiura; Il-Mi Okazaki; Takumi Maruhashi; Taku Okazaki
Journal:  J Biol Chem       Date:  2019-02-13       Impact factor: 5.157

Review 2.  Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance.

Authors:  Tijana Martinov; Brian T Fife
Journal:  Ann N Y Acad Sci       Date:  2019-04-26       Impact factor: 5.691

Review 3.  Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.

Authors:  Elisa Ruffo; Richard C Wu; Tullia C Bruno; Creg J Workman; Dario A A Vignali
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

4.  The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells.

Authors:  Laëtitia Maçon-Lemaître; Frédéric Triebel
Journal:  Immunology       Date:  2005-06       Impact factor: 7.397

Review 5.  LAG3 (CD223) as a cancer immunotherapy target.

Authors:  Lawrence P Andrews; Ariel E Marciscano; Charles G Drake; Dario A A Vignali
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

6.  Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes.

Authors:  David H Wagner; Gisela Vaitaitis; Richard Sanderson; Michelle Poulin; Cathleen Dobbs; Kathryn Haskins
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

7.  Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab.

Authors:  Jon Bjoern; Nikolaj Juul Nitschke; Trine Zeeberg Iversen; Henrik Schmidt; Kirsten Fode; Inge Marie Svane
Journal:  Oncoimmunology       Date:  2015-11-25       Impact factor: 8.110

8.  Lymphocyte activation gene-3 expression defines a discrete subset of HIV-specific CD8+ T cells that is associated with lower viral load.

Authors:  José Peña; Norman G Jones; Stephanie Bousheri; David R Bangsberg; Huyen Cao
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-26       Impact factor: 2.205

Review 9.  Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.

Authors:  Anna Śledzińska; Laurie Menger; Katharina Bergerhoff; Karl S Peggs; Sergio A Quezada
Journal:  Mol Oncol       Date:  2015-10-26       Impact factor: 6.603

Review 10.  Understanding LAG-3 Signaling.

Authors:  Luisa Chocarro; Ester Blanco; Miren Zuazo; Hugo Arasanz; Ana Bocanegra; Leticia Fernández-Rubio; Pilar Morente; Gonzalo Fernández-Hinojal; Miriam Echaide; Maider Garnica; Pablo Ramos; Ruth Vera; Grazyna Kochan; David Escors
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.